Free Trial

Oragenics (OGEN) Competitors

Oragenics logo
$1.39 -0.04 (-2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$1.39 +0.00 (+0.29%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OGEN vs. SNGX, DRMA, RDHL, ALBT, SPRC, VRAX, THAR, TTNP, PBM, and EVAX

Should you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include Soligenix (SNGX), Dermata Therapeutics (DRMA), Redhill Biopharma (RDHL), Avalon GloboCare (ALBT), SciSparc (SPRC), Virax Biolabs Group (VRAX), Tharimmune (THAR), Titan Pharmaceuticals (TTNP), Psyence Biomedical (PBM), and Evaxion A/S (EVAX). These companies are all part of the "pharmaceutical products" industry.

Oragenics vs. Its Competitors

Soligenix (NASDAQ:SNGX) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Soligenix's return on equity of -223.89% beat Oragenics' return on equity.

Company Net Margins Return on Equity Return on Assets
SoligenixN/A -223.89% -103.50%
Oragenics N/A -2,087.95%-486.56%

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 4.9% of Oragenics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Soligenix has higher revenue and earnings than Oragenics. Soligenix is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soligenix$120K35.86-$8.27M-$4.29-0.31
OragenicsN/AN/A-$20.66M-$33.63-0.04

In the previous week, Soligenix had 2 more articles in the media than Oragenics. MarketBeat recorded 2 mentions for Soligenix and 0 mentions for Oragenics. Soligenix's average media sentiment score of 0.60 beat Oragenics' score of 0.00 indicating that Soligenix is being referred to more favorably in the media.

Company Overall Sentiment
Soligenix Positive
Oragenics Neutral

Soligenix presently has a consensus target price of $6.00, indicating a potential upside of 354.55%. Given Soligenix's stronger consensus rating and higher possible upside, analysts plainly believe Soligenix is more favorable than Oragenics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oragenics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Soligenix has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Summary

Soligenix beats Oragenics on 11 of the 14 factors compared between the two stocks.

Get Oragenics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGEN vs. The Competition

MetricOragenicsPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$1.18M$776.90M$5.70B$21.12B
Dividend YieldN/A4.84%4.69%3.60%
P/E Ratio-0.201.4028.0728.44
Price / SalesN/A25.35448.5760.38
Price / CashN/A19.5636.2222.92
Price / Book2.286.798.664.69
Net Income-$20.66M-$4.32M$3.25B$995.51M
7 Day Performance2.96%1.33%4.20%1.64%
1 Month Performance-59.83%3.74%10.82%5.92%
1 Year Performance-95.41%8.18%34.70%11.50%

Oragenics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGEN
Oragenics
0.1024 of 5 stars
$1.39
-2.8%
N/A-95.5%$1.18MN/A-0.205
SNGX
Soligenix
2.5923 of 5 stars
$1.43
+1.4%
$6.00
+319.6%
-70.8%$4.66M$120K-0.3320
DRMA
Dermata Therapeutics
2.7921 of 5 stars
$0.73
+4.3%
$3.00
+312.7%
-73.8%$4.64MN/A-0.048
RDHL
Redhill Biopharma
N/A$1.99
-8.5%
N/A-99.2%$4.64M$8.04M0.00210Gap Up
ALBT
Avalon GloboCare
3.1629 of 5 stars
$2.39
-1.4%
N/A-63.0%$4.55M$1.33M-0.125Positive News
Gap Up
SPRC
SciSparc
0.8628 of 5 stars
$8.27
+1.0%
N/A-34.3%$4.38M$1.31M0.004
VRAX
Virax Biolabs Group
2.4895 of 5 stars
$1.00
-2.0%
$3.00
+201.5%
-6.4%$4.37M$10K0.005
THAR
Tharimmune
3.0679 of 5 stars
$1.64
+1.2%
$17.00
+936.6%
-51.1%$4.36MN/A-0.212
TTNP
Titan Pharmaceuticals
0.304 of 5 stars
$4.69
-1.9%
N/A-14.2%$4.27M$180K-1.0210Positive News
Gap Up
PBM
Psyence Biomedical
0.755 of 5 stars
$7.27
+0.3%
N/A-95.7%$4.08MN/A0.00N/A
EVAX
Evaxion A/S
2.8499 of 5 stars
$2.73
+4.4%
$10.00
+267.0%
-82.0%$3.82M$3.29M-2.3560Gap Down

Related Companies and Tools


This page (NYSE:OGEN) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners